MedTrace Logo

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

NCT05132413 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 561

Last updated 2021-11-24

No results posted yet for this study

Summary

Evaluate efficacy and safety of SHR-1701 in combination with bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small-cell lung cancer with EGFR mutation after failure of TKIs

Conditions

  • Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer

Interventions

DRUG

SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab

SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab

DRUG

Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin

Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin

DRUG

Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin

Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-30
Primary Completion
2024-12-30
Completion
2024-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05132413 on ClinicalTrials.gov